Company profile
Omeros Corporation
NASDAQ: OMER · Healthcare · Biotechnology
#386 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
65BFH 68DQ 57GM 67SS 74
v0.1 · 65/100 weight · provisional
↑ Piotroski F, revenue growth (YoY) · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$38.4M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.4M
Employees
175
as of 2026-08-11
Market cap
$985.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$73.8M$73.8M2020
Net income-$3.4M-$3.4M2025
Operating income-$122.8M-$122.8M2025
Total assets$325.6M$325.6M2025
Equity-$121.2M-$121.2M2025
Revenue trend
FY2019 – FY2020 · USD
FY19
FY19
FY19
FY19
FY20
FY20
FY20
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Omeros Corporation’s revenue?
Omeros Corporation booked $73.8M in FY2020 revenue, growing 183% year over year — faster than most Healthcare companies we track, at a -4.5% net margin.
Peers · Healthcare
AbCellera Biologics Inc.54DRecursion Pharmaceuticals, Inc.54DHealwell AI Inc.60CAssembly Biosciences, Inc.63CCue Health Inc.——Avita Medical Inc.50DNeighbors
King →Key facts
CEOGregory A. Demopulos
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeNASDAQ: OMER
Employees175
IPO date2009-10-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.